Firecrest platform offers unique capabilities for improving the quality, consistency and compliance of ICH/GCP training
Dublin, Ireland, 14th April, 2014 – ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that its Firecrest training meets TransCelerate BioPharma Inc.’s minimum criteria for International Conference on Harmonisation Good Clinical Practice (ICH/GCP) training.
TransCelerate-certified GCP training enables investigators to complete GCP training that is mutually acceptable by all TransCelerate member companies. Investigators completing the training will avoid having to repeatedly complete pre-qualification GCP training for every trial and can instead focus on study-specific activities that accelerate the delivery of therapies to patients.
ICON’s Firecrest GCP training offers some unique capabilities that are currently unavailable in other GCP training programmes. Sponsors can assign training requirements per specific job role, track training compliance and notify users of overdue training or re-certification due dates. In addition, the programme offers enhanced reporting capabilities that allow biopharma companies to analyse and report completion metrics at a region, site or role level.
Commenting on the announcement, Dr. Steve Cutler, Chief Operating Officer, ICON plc, said: “ICON’s Firecrest technology platform delivers an innovative suite of training, performance support and study management tools which have proven to enhance the compliance, consistency and execution of study-related activities by study personnel. We are pleased that the TransCelerate member companies recognise that our Firecrest GCP training module reflects their best practices for training.”
TransCelerate BioPharma Inc. is a non-profit organisation dedicated to accelerating and simplifying the research and development of innovative new therapies. The organisations' mission is to collaborate across the global biopharmaceutical R&D community to identify, prioritise, design and facilitate implementation of solutions designed to drive the efficient, effective and high quality delivery of new medicines. The founding member companies are AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, the Roche Group, and Sanofi. Additional members that have joined since the inception of TransCelerate include Allergan, Inc., Astellas Pharma Inc., Biogen Idec, Cubist Pharmaceuticals, EMD Serono, Inc., Forest Research Institute, Medgenics, Inc., Shionogi & Co., Ltd. and UCB.
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has approximately 10,300 employees, operating from 77 locations in 38 countries.
Further information is available at www.iconplc.com
ICON Media Contact
Rebecca Power
Weber Shandwick
Tel: +44 (0) 207 067 0866
[email protected]